Digital droplet PCR for T315I BCR::ABL1 KD mutation assessment in adult Ph-positive acute lymphoblastic leukemia with a minimal residual disease increase.

This document discusses the use of digital droplet PCR (ddPCR) as a tool for detecting the T315I mutation in Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). The T315I mutation is associated with resistance to tyrosine kinase inhibitors (TKIs), which are commonly used in the treatment of Ph+ ALL. The study found that ddPCR was as sensitive as Sanger sequencing (SS) for detecting the T315I mutation, and in some cases, ddPCR was more sensitive than SS at low levels of minimal residual disease (MRD). This suggests that ddPCR could be a valuable tool for anticipating relapse in Ph+ ALL patients. The article discusses the use of digital droplet PCR (ddPCR) as a sensitive tool for detecting minimal residual disease (MRD) and predicting relapse in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). The study found that ddPCR was at least as sensitive as real-time quantitative PCR (RQ-PCR) in detecting MRD and could identify mutations in the BCR-ABL1 kinase domain (KD) before an increase in MRD levels. The authors suggest that ddPCR could be used to guide treatment decisions and improve outcomes for Ph+ ALL patients. Further research is needed to validate these findings and determine the clinical value of ddPCR in this context. [Extracted from the article]